Arbaclofen - Seaside Therapeutics
Alternative Names: R-baclofen; STX-209Latest Information Update: 20 Sep 2023
At a glance
- Originator Seaside Therapeutics
- Developer Seaside Therapeutics; The Childrens Hospital of Philadelphia; UMC
- Class Aminobutyric acids; Behavioural disorder therapies; Gastrokinetics; Muscle relaxants; Small molecules
- Mechanism of Action GABA B receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Fragile X syndrome
- Phase II Autistic disorder